vaccin
effect
strategi
prevent
control
influenza
time
product
deploy
season
influenza
vaccin
base
understand
epidemiolog
influenza
global
diseas
virolog
surveil
experi
season
influenza
vaccin
guid
initi
develop
pandem
influenza
vaccin
larg
invest
pandem
influenza
vaccin
last
decad
result
much
progress
bodi
inform
appli
refin
establish
paradigm
critic
complementari
consider
pandem
influenza
vaccin
includ
improv
assess
pandem
potenti
anim
influenza
virus
proactiv
develop
deploy
pandem
influenza
vaccin
applic
novel
platform
strategi
vaccin
product
administr
two
influenza
subtyp
current
cocircul
influenza
b
virus
human
vaccin
effect
strategi
prevent
control
influenza
associ
morbid
mortal
strain
select
manufactur
deploy
season
influenza
vaccin
control
virus
becom
routin
compon
nation
health
program
mani
countri
antigen
drift
ha
protein
necessit
annual
reformul
season
vaccin
maxim
vaccin
efficaci
predict
influenza
variant
domin
given
influenza
season
challeng
task
base
global
surveil
circul
influenza
virus
lead
time
reactiv
approach
control
season
influenza
sever
month
four
season
vaccin
formul
select
implement
northern
hemispher
fail
adequ
match
epidem
strain
new
antigen
variant
emerg
vaccin
strain
composit
decis
made
mismatch
event
occur
similar
frequenc
southern
hemispher
recent
year
assess
pandem
potenti
anim
influenza
virus
complex
task
four
pandem
influenza
last
centuri
addit
interpandem
period
punctuat
occasion
epidem
caus
virus
unusu
properti
exampl
enhanc
pathogen
transmiss
certain
subgroup
popul
furthermor
sever
avian
influenza
virus
aiv
caus
sporad
zoonot
infect
human
although
humantohuman
transmiss
zoonot
virus
effici
potenti
acquir
properti
render
pandem
threat
public
health
respons
pandem
rapid
includ
develop
deploy
monoval
vaccin
howev
product
distribut
rapid
enough
prevent
second
wave
pandem
effect
control
pandem
influenza
may
therefor
requir
differ
philosoph
approach
establish
paradigm
control
season
influenza
virus
proactiv
pandem
vaccin
strategi
reli
three
critic
element
time
identif
virus
pandem
potenti
proactiv
develop
character
vaccin
develop
improv
vaccin
articl
summar
new
develop
open
question
area
continu
rise
number
anim
human
case
avian
infect
sporad
case
infect
subtyp
virus
direct
call
action
improv
understand
public
health
threat
pose
aiv
virolog
surveil
livestock
poultri
wild
bird
critic
first
step
catalog
circul
aiv
tool
assess
pandem
potenti
need
guid
prepared
effort
develop
standard
object
criteria
pandem
risk
assess
subject
much
debat
us
cdc
propos
standard
influenza
risk
assess
tool
irat
evalu
pandem
potenti
influenza
virus
current
circul
human
framework
base
ten
key
element
includ
spectrum
factor
repres
molecular
biolog
attribut
viru
attribut
popul
epidemiolog
viru
agre
upon
panel
expert
weight
reflect
rel
import
howev
irat
framework
must
updat
new
understand
molecular
determin
transmiss
pathogenesi
aiv
emerg
one
exampl
multibas
cleavag
site
seen
avian
influenza
distinguish
highli
pathogen
low
pathogen
aiv
poultri
virul
motif
mammalian
model
influenza
anoth
exampl
recent
identif
minimum
set
adapt
mutat
necessari
airborn
transmiss
avian
virus
among
ferret
studi
confirm
import
receptor
bind
specif
exist
irat
element
polymeras
activ
also
identifi
acid
stabil
ha
novel
factor
influenc
transmiss
aiv
defi
simpl
classif
regard
pandem
risk
assess
exampl
avian
virus
associ
hand
mild
human
infect
may
classifi
intermedi
pandem
risk
howev
aiv
caus
sever
human
diseas
deriv
intern
protein
gene
virus
anoth
exampl
gene
constel
effect
variant
viru
product
reassort
circul
swine
influenza
virus
viru
caus
mild
diseas
children
usa
detect
sporad
human
sinc
final
virul
human
difficult
predict
exampl
zoonot
transmit
avian
virus
caus
appar
diseas
wild
bird
poultri
caus
sever
respiratori
diseas
human
similarli
precursor
viru
circul
decad
without
caus
appar
diseas
swine
yet
transmiss
human
result
first
influenza
pandem
centuri
aiv
continu
evolv
natur
divers
present
major
challeng
decid
strain
subtyp
target
vaccin
develop
consequ
human
antigen
drift
anim
speci
well
understood
veterinari
vaccin
power
tool
use
control
aiv
outbreak
poultri
howev
largescal
vaccin
livestock
afford
part
world
furthermor
vaccin
may
confound
serolog
surveil
effort
earli
detect
aiv
domest
poultri
unless
vaccin
design
serolog
detect
assay
direct
differ
viral
protein
strategi
refer
differenti
infect
vaccin
anim
diva
approach
howev
grow
avail
aiv
sequenc
data
increasingli
widespread
laboratori
capac
molecular
surveil
potenti
abrog
problem
final
suboptim
vaccin
via
poor
vaccin
coverag
use
mismatch
vaccin
may
result
nonsteril
immun
morbid
mortal
poultri
reduc
viral
replic
still
occur
may
drive
viral
escap
promot
endem
escap
variant
manner
suboptim
vaccin
may
drive
antigen
drift
provid
opportun
reassort
human
virus
therebi
potenti
increas
chanc
zoonot
transmiss
mathemat
model
spread
pandem
influenza
viru
suggest
intervent
week
follow
initi
recognit
pandem
greatest
potenti
effect
respons
term
human
morbid
econom
cost
product
licens
season
influenza
vaccin
take
month
sever
opportun
exist
framework
influenza
vaccin
product
acceler
respons
critic
consider
event
pandem
figur
first
preclin
clinic
evalu
safeti
immunogen
candid
pandem
influenza
vaccin
interpandem
period
enhanc
pandem
prepared
second
creation
librari
vaccin
seed
stock
may
substanti
reduc
lead
time
vaccin
product
third
new
technolog
revers
genet
synthet
biolog
facilit
acceler
product
vaccin
virus
fourth
deploy
vaccin
prior
pandem
prepandem
vaccin
propos
circumv
delay
associ
distribut
new
vaccin
midst
pandem
proactiv
approach
without
preced
sever
vaccin
licens
usa
europ
stockpil
vaccin
compon
pandem
influenza
prepared
framework
howev
safeti
immunogen
vaccin
subtyp
would
establish
clinic
trial
experi
season
influenza
vaccin
demonstr
antigen
drift
gradual
accumul
antigen
chang
influenza
viru
surfac
glycoprotein
profound
effect
vaccin
efficaci
closer
antigen
match
vaccin
strain
epidem
strain
greater
efficaci
vaccin
import
note
antigen
differ
determin
use
postinfect
ferret
antisera
increas
evid
individu
immun
histori
import
determin
specif
antibodi
respons
therefor
data
ferret
follow
primari
infect
may
accur
reflect
would
happen
influenzaexperienc
human
case
trival
inactiv
influenza
vaccin
iiv
compar
vaccin
season
laiv
administ
children
superior
trival
iiv
abil
protect
drift
virus
contain
vaccin
contrast
efficaci
season
iiv
equal
superior
laiv
adult
possibl
adult
immunolog
prime
previou
influenza
infect
vaccin
howev
neither
laiv
iiv
efficaci
mismatch
circul
viru
season
season
influenza
vaccin
provid
variabl
protect
drift
variant
composit
modifi
new
antigen
variant
epidem
potenti
identifi
antigen
drift
pose
challeng
novel
antigen
well
phylogenet
analysi
avian
reveal
diversif
multipl
distinct
clade
similar
divers
may
occur
aiv
subtyp
past
year
eight
new
clade
virus
includ
fifth
order
subclad
emerg
clear
whether
clade
pose
equival
pandem
risk
event
pandem
vaccin
differ
clade
may
prevent
infect
may
still
prevent
sever
diseas
death
estim
pandem
vaccin
efficaci
low
would
substanti
impact
limit
morbid
mortal
would
cost
effect
reactiv
pandem
respons
furthermor
recent
character
pandem
influenza
vaccin
advanc
immunolog
suggest
exact
match
vaccin
strain
pandem
strain
may
necessari
includ
discoveri
conserv
epitop
influenza
ha
independ
contribut
tcellmedi
immun
crossprotect
immun
empir
evid
phase
clinic
trial
crossreact
serum
antibodi
respons
elicit
pandem
vaccin
candid
improv
vaccin
formul
conserv
epitop
elicit
crossprotect
immunityth
identif
conserv
epitop
ha
stalk
target
neutral
antibodi
support
concept
mismatch
vaccin
may
provid
crossprotect
stalkreact
antibodi
detect
sera
individu
follow
infect
immun
season
influenza
vaccin
adjuv
split
virion
vaccin
cellmedi
immun
elicit
conserv
tcell
epitop
also
independ
contribut
crossprotect
immun
although
cellmedi
immun
prevent
infect
tcell
respons
enhanc
viral
clearanc
protect
sever
diseas
death
preclin
model
syngen
tcell
transfer
tcell
deplet
studi
vaccin
influenza
virusinfect
mice
establish
role
cellmedi
crossprotect
lethal
challeng
heterolog
influenza
virus
human
challeng
studi
viru
presenc
preexist
crossreact
influenzaspecif
cell
correl
protect
sever
ill
decreas
shed
pandem
presenc
crossreact
cell
correl
protect
influenza
viru
infect
vaccin
elicit
influenzaspecif
cell
crossclad
heterosubtyp
reactiv
furthermor
tcell
respons
conserv
epitop
influenza
protein
nucleoprotein
associ
protect
sever
ill
pandem
influenza
vaccin
candid
develop
sever
platform
found
elicit
crossclad
immun
preclin
model
clinic
studi
inactiv
live
attenu
vaccin
highli
effect
ferret
mice
lethal
challeng
homolog
heterolog
virus
differ
clade
similarli
liveattenu
vaccin
virus
elicit
subtypespecif
crossreact
serum
antibodi
reduc
replic
homolog
heterolog
challeng
virus
mice
ferret
inactiv
monoval
vaccin
candid
confer
protect
lethal
challeng
mice
influenza
viru
pandem
influenza
vaccin
also
induc
antibodi
respons
heterolog
virus
human
adjuv
subunit
vaccin
contain
ha
avian
viru
elicit
serum
neutral
antibodi
respons
sever
clinic
isol
collect
period
adjuv
inactiv
whole
virion
split
virion
vaccin
elicit
neutral
antibodi
homolog
viru
drift
virus
repres
distinct
clade
children
adult
elderli
furthermor
vaccin
elicit
memori
bcell
respons
upper
respiratori
mucosa
enhanc
crossprotect
respons
ongo
challeng
seen
import
step
develop
univers
influenza
vaccin
recent
studi
directli
compar
differ
formul
pandem
influenza
vaccin
demonstr
choic
vaccin
platform
inclus
adjuv
influenc
breadth
qualiti
immun
respons
improv
vaccin
formul
potenti
elicit
protect
greater
breadth
influenza
viru
subtyp
novel
formul
may
also
elicit
protect
immun
mechan
antibodydepend
cellular
cytotox
adcc
mediat
nonneutr
antibodi
previous
state
grow
evid
exposur
immun
histori
also
influenc
immun
respons
influenza
vaccin
serolog
studi
suggest
previou
exposur
constrain
bcell
respons
novel
antigen
context
season
influenza
vaccin
fact
suggest
administr
novel
antigen
preferenti
elicit
antibodi
conserv
epitop
share
exist
season
influenza
virus
vaccin
elicit
antibodi
broad
crossreact
adult
safetyth
manufactur
pandem
influenza
vaccin
pose
uniqu
safeti
concern
manufactur
protocol
must
care
design
implement
reduc
risk
exposur
novel
virus
two
strategi
propos
mitig
risk
use
less
pathogen
virus
subtyp
product
vaccin
use
revers
geneticsderiv
virus
bear
recombin
ha
known
pathogen
determin
remov
pandem
laiv
plaiv
number
theoret
advantag
iiv
includ
superior
abil
elicit
mucos
cellular
immun
respons
needlefre
administr
greater
yield
clinic
studi
control
set
demonstr
replic
plaiv
candid
significantli
restrict
healthi
adult
vaccin
viru
shed
low
titer
subset
vaccin
recipi
howev
contain
replic
albeit
attenu
viru
possibl
plaiv
viru
could
reassort
circul
influenza
virus
outcom
event
may
viru
novel
ha
potenti
spread
commun
therefor
plaiv
would
use
recommend
public
health
offici
like
pandem
inevit
howev
proactiv
gener
evalu
librari
plaiv
rang
ha
subtyp
allow
rapid
product
vaccin
need
howev
rare
unexpect
advers
event
may
seen
vaccin
administ
larg
popul
one
formul
adjuv
splitvirion
inactiv
vaccin
market
europ
associ
increas
incid
narcolepsi
children
young
adult
interestingli
differ
formul
monoval
vaccin
monoval
vaccin
associ
narcolepsi
possibl
differ
antigen
process
adjuv
formul
contribut
observ
differ
host
factor
could
also
influenc
safeti
outcom
observ
vaccin
narcolepsi
associ
genet
loci
influenc
antigen
present
tcell
differenti
age
also
identifi
risk
factor
develop
narcolepsi
follow
exposur
via
either
immun
infect
complex
narcolepsypandem
influenza
issu
recent
review
studi
necessari
clarifi
issu
effect
control
pandem
vaccin
requir
rapid
develop
evalu
deploy
safe
efficaci
product
novel
vaccin
target
platform
adjuv
formul
offer
great
promis
benefit
decad
clinic
experi
licens
vaccin
postmarket
surveil
advers
event
provid
critic
safeti
data
although
clear
serum
antibodi
correl
protect
influenza
sole
relianc
serum
hai
titer
evalu
vaccin
problemat
number
reason
first
correl
relev
influenza
vaccin
contain
globular
head
ha
protein
mediat
hemagglutin
activ
hai
assay
fail
detect
potenti
function
antibodi
bind
ha
stem
epitop
viral
protein
addit
serum
antibodi
titer
ignor
contribut
cellmedi
immun
requir
clearanc
viru
innat
immun
respons
propos
play
role
influenza
pathogen
final
hai
titer
robust
correl
protect
laiv
known
whether
licens
criteria
appli
season
influenza
vaccin
appropri
pandem
influenza
vaccin
differ
criteria
may
appropri
differ
popul
furthermor
known
correl
immunolog
prime
would
import
novel
pandem
vaccin
may
meet
classic
criteria
hai
immunogen
prime
robust
respons
follow
administr
booster
vaccin
critic
research
prioriti
therefor
identif
valid
addit
correl
protect
influenza
attract
approach
identif
potenti
correl
largescal
highthroughput
analysi
antibodi
repertoir
convalesc
serum
survivor
aiv
infect
could
use
probe
librari
peptid
repres
viral
genom
antigen
fingerprint
order
identifi
key
viral
antigen
epitop
furthermor
develop
applic
adcc
cellular
immun
assay
also
enhanc
understand
vaccinemedi
protect
laiv
vaccin
develop
usa
russia
elicit
compar
serolog
respons
season
laiv
phase
iii
clinic
trial
usa
monoval
laiv
elicit
seroconvers
rate
adult
age
two
dose
vaccin
phase
iii
clinic
trial
conduct
russian
formul
monoval
laiv
elicit
similar
serum
hai
antibodi
respons
modest
increas
frequenc
virusspecif
memori
cell
report
peripher
circul
healthi
adult
formul
immunogen
slightli
higher
children
year
age
compar
adult
sever
adjuv
unadjuv
iiv
also
character
usa
europ
found
robustli
immunogen
singl
dose
unadjuv
iiv
immunogen
age
group
year
age
inclus
adjuv
iiv
formul
permit
dose
spare
equival
quarter
dose
ha
antigen
compar
immunogen
unadjuv
formul
plaiv
aiv
shown
promis
preclin
studi
first
target
plaiv
viru
vaccin
immunogen
healthi
seroneg
adult
two
dose
elicit
seroconvers
vaccin
recipi
similarli
laiv
two
differ
backbon
target
aiv
immunogen
healthi
seroneg
adult
elicit
seroconvers
rate
receiv
two
dose
vaccin
phase
clinic
trial
suggest
plaivbear
novel
antigen
deriv
aiv
elicit
serum
antibodi
respons
howev
plaiv
equal
immunogen
two
plaiv
repres
distinct
virus
demonstr
great
promis
preclin
studi
fail
elicit
robust
serum
neutral
antibodi
respons
phase
clinic
trial
recombin
ha
unadjuv
iiv
also
poorli
immunogen
human
notabl
howev
laiv
recombin
ha
vaccin
prime
robust
respons
subsequ
iiv
novel
vaccin
formul
combin
exist
vaccin
platform
offer
great
promis
enhanc
immunogen
expand
breadth
immun
critic
characterist
ideal
pandem
influenza
vaccin
mass
vaccin
respons
swine
flu
outbreak
provid
clear
demonstr
impact
prime
immunogen
novel
vaccin
singl
dose
split
subunit
vaccin
immunogen
among
older
individu
prime
previou
exposur
relat
virus
lifetim
howev
higher
dose
antigen
administ
either
addit
dose
vaccin
singl
dose
vaccin
formul
antigen
necessari
elicit
compar
respons
immunolog
naiv
younger
individu
primeboost
schedul
pandem
vaccin
evalu
numer
clinic
studi
two
dose
live
attenu
prototyp
vaccin
highli
immunogen
seroneg
individu
typic
candid
plaiv
howev
combin
differ
vaccin
platform
demonstr
promis
improv
immunogen
prototyp
pandem
vaccin
illustr
clearli
evalu
pandem
vaccin
sequenti
use
inactiv
vaccin
follow
prime
dna
recombin
ha
vector
ha
laiv
inactiv
vaccin
elicit
robust
neutral
antibodi
respons
booster
vaccin
iiv
could
rapidli
elicit
serum
antibodi
respons
even
interv
primari
secondari
vaccin
year
similar
result
found
influenza
vaccin
interv
month
plaiv
piiv
furthermor
primeboost
strategi
elicit
crossreact
serum
antibodi
primari
vaccin
plaiv
dna
vector
vaccin
follow
homolog
iiv
elicit
antibodi
crossclad
neutral
activ
similarli
booster
dose
vaccin
deliv
month
primari
vaccin
elicit
crossclad
antibodi
respons
sequenti
vaccin
antigen
mismatch
vaccin
also
elicit
serum
antibodi
crossclad
neutral
activ
individu
prime
vaccin
boost
inactiv
vaccin
elicit
high
titer
crossclad
neutral
serum
antibodi
within
day
administr
recombin
baculovirusexpress
ha
subunit
vaccin
prime
robust
crossclad
recal
respons
upon
boost
antigen
distinct
inactiv
subvirion
vaccin
year
later
final
sequenti
administr
antigen
mismatch
vaccin
may
use
modul
antibodi
respons
ha
stalk
suggest
sequenti
administr
antigen
distinct
ha
antigen
select
elicit
robust
antibodi
respons
conserv
less
immunodomin
ha
stalk
stem
stem
antibodi
often
potent
broad
crossneutr
activ
poorli
elicit
vaccin
monoval
inactiv
vaccin
contrast
prime
plaiv
dna
vaccin
prior
vaccin
pandem
iiv
effici
elicit
high
affin
stem
antibodi
studi
suggest
proactiv
primeboost
approach
pandem
prepared
consid
booster
vaccin
could
administ
vaccineprim
popul
pandem
threat
materi
prepandem
vaccin
prime
could
potenti
coupl
season
influenza
vaccin
suggest
concurr
administr
season
trival
iiv
neg
affect
safeti
immunogen
either
vaccin
sequenti
administr
could
slightli
attenu
immunogen
inactiv
vaccin
underli
immunolog
mechan
whether
would
appli
pandem
vaccin
contain
complet
novel
ha
subtyp
known
howev
result
studi
well
phase
iii
evalu
prototyp
pandem
vaccin
describ
suggest
robust
serum
antibodi
respons
achiev
despit
prior
season
influenza
vaccin
primeboost
strategi
deliveri
pandem
influenza
vaccin
show
promis
even
older
age
group
effect
season
influenza
vaccin
suboptim
least
two
formul
inactiv
vaccin
shown
prime
rapid
robust
serumneutr
antibodi
respons
heterolog
inactiv
booster
vaccin
elderli
cohort
product
adequ
suppli
vaccin
short
period
time
major
challeng
number
reason
includ
need
facil
meet
good
manufactur
practic
gmp
standard
depend
egg
product
lead
time
requir
gener
vaccin
exist
platform
first
step
select
character
vaccin
seed
viru
amplifi
embryon
egg
cell
cultur
produc
antigen
depend
chicken
egg
amplif
critic
weak
seed
viru
pathogen
andor
grow
poorli
egg
final
vaccin
must
formul
purifi
prepar
distribut
eggbas
amplif
vaccin
seed
stock
improv
introduct
mutat
enhanc
amplif
embryon
egg
without
compromis
antigen
inde
grow
evid
substitut
particularli
influenc
stabil
ha
enhanc
immunogen
live
attenu
avian
influenza
candid
vaccin
preclin
model
howev
adapt
mutat
introduc
amplif
influenza
virus
egg
mammalian
cell
line
may
impair
immunogen
vaccin
therefor
thorough
character
vaccin
seed
stock
necessari
novel
platform
depend
infecti
viru
circumv
need
eggbas
amplif
mitig
risk
human
vaccin
product
proof
principl
cellbas
amplif
viru
laiv
iiv
establish
vaccin
season
influenza
produc
mammalian
cell
line
flucelvax
licens
fda
mammalian
cell
cultur
deriv
vaccin
also
shown
welltoler
immunogen
candid
includ
vaccin
show
promis
preclin
model
vaccin
like
safe
individu
allerg
egg
furthermor
recombin
influenza
viru
protein
express
varieti
cell
line
includ
insect
cell
plant
cell
solubl
protein
noninfecti
viruslik
particl
approach
offer
opportun
modul
immun
respons
genet
engin
influenza
viru
antigen
dna
vaccin
anoth
altern
tradit
influenza
vaccin
platform
deliv
subcutan
intramuscularli
reli
host
cell
inject
site
express
present
viral
protein
immun
system
dna
vaccin
produc
larg
quantiti
stabl
facilit
stockpil
vaccin
altern
vaccin
technolog
deliv
viral
antigen
via
replicationdefect
vector
adenoviru
modifi
vaccinia
viru
ankara
demonstr
safe
immunogen
human
platform
share
advantag
plaiv
stimul
robust
cellmedi
antibodymedi
immun
respons
without
risk
introduct
novel
pandem
influenza
gene
season
influenza
virus
influenza
vaccin
candid
use
vector
includ
adenoassoci
virus
alphavirus
newcastl
diseas
viru
vesicular
stomat
viru
demonstr
promis
deliveri
express
influenza
antigen
varieti
preclin
model
yet
evalu
human
final
inclus
adjuv
vaccin
formul
great
potenti
enhanc
magnitud
serum
antibodi
respons
facilit
stimul
mucos
cellmedi
immun
enhanc
longev
serum
antibodi
respons
follow
vaccin
inclus
subunit
vaccin
formul
enhanc
qualiti
breadth
serum
antibodi
respons
furthermor
inclus
adjuv
permit
dose
spare
lower
antigen
dose
elicit
respons
suffici
meet
immunogen
criteria
therebi
increas
number
dose
avail
vaccin
event
pandem
two
formul
pandem
vaccin
deploy
effort
control
pandem
adjuv
oilinwat
emuls
found
permit
dose
spare
enhanc
magnitud
persist
serum
hai
titer
rel
elicit
unadjuv
vaccin
howev
associ
narcolepsi
countri
illustr
safeti
regulatori
challeng
novel
vaccin
formul
platform
pandem
influenza
vaccin
proactiv
approach
pandem
influenza
vaccin
requir
intern
collabor
share
commit
surveil
research
character
pandem
vaccin
foundat
alreadi
laid
approach
much
progress
made
past
decad
establish
formal
pandem
influenza
prepared
plan
illustr
shift
toward
proactiv
pandem
prepared
usa
plan
call
increas
support
influenza
research
establish
framework
interag
collabor
recommend
increas
surveil
influenza
virus
anim
popul
sinc
undergon
period
refin
increas
recognit
fundament
overlap
veterinari
human
public
health
embodi
one
health
initi
formal
launch
illustr
grow
number
countri
influenza
surveil
program
anim
popul
intern
collabor
expert
result
refin
pandem
prepared
plan
notabl
among
pandem
influenza
prepared
framework
provid
framework
share
influenza
viru
sequenc
data
access
diagnost
test
vaccin
sinc
new
tool
pandem
risk
assess
novel
platform
strategi
vaccin
pave
way
improv
pandem
prepared
next
year
like
aiv
alreadi
enzoot
asia
becom
establish
avian
speci
part
world
prompt
reexamin
agricultur
practic
greater
emphasi
biosecur
develop
vaccin
veterinari
human
use
near
term
discuss
focu
pro
con
novel
vaccin
formul
especi
adjuv
vector
vaccin
schedul
sequenti
use
vaccin
base
differ
platform
longer
term
newer
technolog
approach
develop
vaccin
induc
broader
immun
progress
ultim
goal
univers
influenza
vaccin
howev
regulatori
path
licensur
vaccin
mediat
protect
induct
antibodi
ha
head
yet
clear
success
implement
novel
ultim
univers
influenza
vaccin
requir
develop
assay
measur
correl
protect
vaccin
parallel
advanc
regulatori
scienc
season
influenza
vaccin
formul
use
alreadi
licens
technolog
process
timelin
exist
framework
strain
select
season
vaccin
deploy
month
step
process
develop
deploy
pandem
vaccin
may
acceler
indic
arrow
